User login
MADRID – From CLEOPATRA to IMELDA and TANIA, Dr. Hope S. Rugo shared her insights on these three breast cancer trials and more making headlines at the European Society for Medical Oncology Congress.
The final overall survival analysis from the phase III CLEOPATRA trial is certainly the blockbuster in breast cancer at the meeting in Madrid, establishing a new treatment regimen of dual targeted therapy plus chemotherapy in first-line HER2-positive metastatic disease.
Other breast cancer trials, such as IMELDA, TANIA, and RESILIENCE, provide a mixture of thought-provoking results for practicing oncologists, according to Dr. Rugo, director of the breast oncology clinical trials program at the University of California, San Francisco.
Dr. Rugo reported financial relationships with Genomic Health, Merck, Novartis, and Plexxikon.
MADRID – From CLEOPATRA to IMELDA and TANIA, Dr. Hope S. Rugo shared her insights on these three breast cancer trials and more making headlines at the European Society for Medical Oncology Congress.
The final overall survival analysis from the phase III CLEOPATRA trial is certainly the blockbuster in breast cancer at the meeting in Madrid, establishing a new treatment regimen of dual targeted therapy plus chemotherapy in first-line HER2-positive metastatic disease.
Other breast cancer trials, such as IMELDA, TANIA, and RESILIENCE, provide a mixture of thought-provoking results for practicing oncologists, according to Dr. Rugo, director of the breast oncology clinical trials program at the University of California, San Francisco.
Dr. Rugo reported financial relationships with Genomic Health, Merck, Novartis, and Plexxikon.
MADRID – From CLEOPATRA to IMELDA and TANIA, Dr. Hope S. Rugo shared her insights on these three breast cancer trials and more making headlines at the European Society for Medical Oncology Congress.
The final overall survival analysis from the phase III CLEOPATRA trial is certainly the blockbuster in breast cancer at the meeting in Madrid, establishing a new treatment regimen of dual targeted therapy plus chemotherapy in first-line HER2-positive metastatic disease.
Other breast cancer trials, such as IMELDA, TANIA, and RESILIENCE, provide a mixture of thought-provoking results for practicing oncologists, according to Dr. Rugo, director of the breast oncology clinical trials program at the University of California, San Francisco.
Dr. Rugo reported financial relationships with Genomic Health, Merck, Novartis, and Plexxikon.
AT ESMO 2014
